clorgyline has been researched along with Idiopathic Parkinson Disease in 15 studies
Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.
clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Administration in daily dosage of 10 mgs produces an almost complete inhibition of the enzyme." | 2.37 | R-(-)-deprenyl and parkinsonism. ( Yahr, MD, 1987) |
| "Parkinson disease is characterized by a major loss (approximately 80% or more) of dopaminergic nigrostriatal neurons and by an increased turnover of neurotransmitter by surviving neurons of the nigrostriatal tract." | 1.28 | Dopamine turnover and glutathione oxidation: implications for Parkinson disease. ( Cohen, G; Spina, MB, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (40.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Distinto, S | 1 |
| Yáñez, M | 1 |
| Alcaro, S | 2 |
| Cardia, MC | 1 |
| Gaspari, M | 1 |
| Sanna, ML | 1 |
| Meleddu, R | 1 |
| Ortuso, F | 2 |
| Kirchmair, J | 1 |
| Markt, P | 1 |
| Bolasco, A | 1 |
| Wolber, G | 1 |
| Secci, D | 2 |
| Maccioni, E | 1 |
| Rojas, RJ | 1 |
| Edmondson, DE | 1 |
| Almos, T | 1 |
| Scott, R | 1 |
| Massari, ME | 1 |
| Carradori, S | 1 |
| Petzer, A | 2 |
| Bagetta, D | 1 |
| De Monte, C | 1 |
| De Vita, D | 1 |
| Guglielmi, P | 1 |
| Zengin, G | 1 |
| Aktumsek, A | 1 |
| Petzer, JP | 2 |
| Yeon, SK | 1 |
| Choi, JW | 1 |
| Park, JH | 1 |
| Lee, YR | 1 |
| Kim, HJ | 1 |
| Shin, SJ | 1 |
| Jang, BK | 1 |
| Kim, S | 1 |
| Bahn, YS | 1 |
| Han, G | 1 |
| Lee, YS | 1 |
| Pae, AN | 1 |
| Park, KD | 1 |
| Meiring, L | 1 |
| Legoabe, LJ | 1 |
| Dell'Antone, P | 1 |
| IbnLkayat, M | 1 |
| Drago, D | 1 |
| Zatta, P | 1 |
| Sandler, M | 1 |
| Youdim, MB | 2 |
| Finberg, JP | 1 |
| Wang, J | 1 |
| Goldstein, DS | 1 |
| Kopin, IJ | 1 |
| Bankiewicz, KS | 1 |
| Liptrot, J | 1 |
| Holdup, D | 1 |
| Phillipson, O | 1 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Martínez-Tica, J | 1 |
| Yahr, MD | 2 |
| Holzbauer, M | 1 |
| Knoll, J | 1 |
| Spina, MB | 1 |
| Cohen, G | 1 |
3 reviews available for clorgyline and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Are there MAO inhibitors specific for dopamine metabolism?
Topics: Animals; Binding Sites; Brain; Clorgyline; Dopamine; Drug Synergism; Humans; In Vitro Techniques; Le | 1977 |
On the dual nature of monoamine oxidase.
Topics: Animals; Antidepressive Agents; Binding Sites; Brain; Catecholamines; Clorgyline; Dose-Response Rela | 1978 |
R-(-)-deprenyl and parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benserazide; Clorgyline; Dopamine; Drug Therapy, Combi | 1987 |
12 other studies available for clorgyline and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
Topics: Binding Sites; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Dyn | 2012 |
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries | 2015 |
Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
Topics: Acetylcholinesterase; Animals; Antioxidants; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose- | 2018 |
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzene Derivatives; Disease Models, Animal; | 2018 |
The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Propy | 2022 |
Acidic vesicles of the endo-exocytic pathways as targets for some anti-monoamine oxidase drugs.
Topics: Acid-Base Equilibrium; Acids; Alzheimer Disease; Amantadine; Animals; Brain; Brain Chemistry; Brain | 2009 |
Monoamine oxidase inhibitors and their pharmacological significance.
Topics: Animals; Antidepressive Agents; Brain; Clorgyline; Humans; Monoamine Oxidase; Monoamine Oxidase Inhi | 1983 |
Biochemical characterization of the active site of brain monoamine oxidase.
Topics: Antidepressive Agents; Binding Sites; Brain; Clorgyline; Humans; Mitochondria; Monoamine Oxidase; Mo | 1980 |
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanill | 1995 |
1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol inhibits tyrosine hydroxylase activity in rat striatal synaptosomes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Chromatography, High Pressure Liq | 1994 |
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Homovanillic Acid; L | 1995 |
Dopamine turnover and glutathione oxidation: implications for Parkinson disease.
Topics: Animals; Cerebral Cortex; Clorgyline; Corpus Striatum; Disease Models, Animal; Dopamine; Glutathione | 1989 |